Roland B. Walter

Appointments and Affiliations

Fred Hutchinson Cancer Research Center
Clinical Research Division
Assistant Member, Appointed: 2010
University of Washington
School of Medicine
Assistant Professor, Appointed: 2010
Professional Headshot of Roland B. Walter

Mailing Address

1100 Fairview Ave N
Seattle, Washington 98109-1024
United States


Phone: (206) 667-3599
Fax: (206) 667-6519


M.S., University of Washington, Epidemiology (Clinical Research), 2011.
Ph.D., University of Washington, Experimental Pathology, 2006.
M.D., University of Zurich, Medicine, 1997.

Research Interests

Dr. Walter's laboratory research is focused on human acute myeloid leukemia (AML), in particular on the delineation of the clonal origin of AML, the molecular and phenotypic characterization of AML stem and progenitor cells, and the interaction between AML cells in their environment. A long-term goal of his preclinical studies is the development of novel therapeutic strategies aimed to eradicate AML stem and progenitor cells. Findings from such studies are then translated into the clinic and tested in early phase human trials.

A second research interest of Dr. Walter is the development and conduct of clinical trials in AML. Dr. Walter is currently the Principal Investigator of several early phase clinical trials that test new drugs and drug combinations in AML; he also leads a phase 2 study that explores a strategy of outpatient management of selected AML/MDS patients following intensive induction chemotherapy.


(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)
German: (Fluent, Fluent, Fluent)
Schwyzerdutsch: (Fluent, Fluent, Fluent)


American Society of Hematology

Honors and Awards

2009-2012, Mentored Patient-Oriented Research Career Development Award (K23), National Cancer Institute, National Institutes of Health (NIH), National Institute of Health (NIH)
2006-2009, Special Fellow Career Development Award, Leukemia & Lymphoma Society
2005, SIAK/ESSEX Award in Applied Cancer Research Switzerland
2005, Dr. Ernst Th. Jucker Price for Cancer Research Switzerland
2005-2007, Clinical/Translational Research Scholar Award, American Society of Hematology
2005-2005, Career Development Award, Janggen-Pohn Foundation, Switzerland
2004-2004, Interdisciplinary Dual Mentor Fellowship, Fred Hutchinson Cancer Research Center
2002-2004, Fellowship for Advanced Researchers, Swiss Foundation for Medical-Biological Grants

Previous Positions

2008-2010, Research Associate, Fred Hutchinson Cancer Research Center, Clinical Research Division
2008-2010, Acting Instructor in Medicine, University of Washington, Department of Medicine, Division of Hematology
2005-2007, Fellow, University of Washington, Department of Medicine, Division of Hematology
2002-2008, Post-Doctoral Research Fellow, Fred Hutchinson Cancer Research Center, Clinical Research Division
1999-2002, Resident, University of Zurich, Department of Medicine
1997-1999, Resident, Kantonsspital Chur, Department of Medicine
1996-1997, Research Fellow, University of Zurich, Department of Medicine


  • National Institutes of Health/National Cancer Institute (K23 CA137161): "AML stem cell heterogeneity: implications for gemtuzumab ozogamicin-based therapy", 2009 to 2010.
  • Institute of Translational Health Science (Small Pilot Grant): "Pilot study of early discharge and outpatient management following induction chemotherapy for MDS and non-APL AML", 2009 to 2010.
  • Ronald McDonald House Charities of Southern California and Couples Against Leukemia: "Heterogeneity of stem cell involvement in AML: therapeutic implications for gemtuzumab ozogamicin", 2009 to 2010.
  • National Institutes of Health/National Cancer Institute: "ARRA: a phase 1/2 study of vorinostat in combination with gemtuzumab ozogamicin and azacitidine in patients 50 years of age and older with relapsed/refractory non-APL AML", 2009 to 2011.
  • National Institutes of Health/National Cancer Institute (Cancer Center Support Grant): "Clinical significance of adhesion molecules and extracellular matrix proteins in pediatric AML", 2009 to 2010.
  • Leukemia & Lymphoma Society (Special Fellow Award): "Regulation of cell surface expression and ITIM-dependent internalization/trafficking of CD33, the target for the ant-leukemia immunoconjugate, gemtuzumab ozogamicin", 2006 to 2009.
  • American Society of Hematology (Clinical/Translational Research Scholar Award): "Regulation of ITIM-dependent internalization of CD33, the target for the anti-leukemia immunoconjugate, gemtuzumab ozogamicin (Mylotarg)", 2005 to 2007.
  • Janggen-Pohn Foundation, Switzerland: Career Development Award, 2005 to 2005.
  • Fred Hutchinson Cancer Research Center (Interdisciplinary Dual Mentor Fellowship): "Internalization of anti-CD33 antibodies", 2004 to 2004.
  • Swiss Foundation for Medical-Biological Grants: "Role of multidrug resistance genes and drug transporter proteins in gemtuzumab ozogamicin resistance in CD33+ hematopoietic malignancies", 2002 to 2004.


Recent Publications

Othus, M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB et al..  2015.  Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):559-64. Abstract